Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANIK

ANIK - Anika Therapeutics Inc Stock Price, Fair Value and News

24.83USD+0.21 (+0.85%)Market Closed
Watchlist

Market Summary

USD24.83+0.21
Market Closed
0.85%

ANIK Stock Price

View Fullscreen

ANIK RSI Chart

ANIK Valuation

Market Cap

363.5M

Price/Earnings (Trailing)

-14.79

Price/Sales (Trailing)

2.23

EV/EBITDA

-13.32

Price/Free Cashflow

-32.87

ANIK Price/Sales (Trailing)

ANIK Profitability

EBT Margin

-17.46%

Return on Equity

-9.09%

Return on Assets

-7.49%

Free Cashflow Yield

-3.04%

ANIK Fundamentals

ANIK Revenue

Revenue (TTM)

163.3M

Rev. Growth (Yr)

2.98%

Rev. Growth (Qtr)

-6.4%

ANIK Earnings

Earnings (TTM)

-24.6M

Earnings Growth (Yr)

-57.51%

Earnings Growth (Qtr)

-139.91%

Breaking Down ANIK Revenue

Last 7 days

0.8%

Last 30 days

8.2%

Last 90 days

15.3%

Trailing 12 Months

-20.5%

How does ANIK drawdown profile look like?

ANIK Financial Health

Current Ratio

5.59

Debt/Equity

0.09

Debt/Cashflow

-0.2

ANIK Investor Care

Shares Dilution (1Y)

0.21%

Diluted EPS (TTM)

-1.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023157.5M162.1M163.3M0
2022150.2M151.7M152.4M156.2M
2021129.4M136.8M144.7M147.8M
2020125.3M125.5M127.5M130.5M
2019109.0M108.9M111.8M114.6M
2018111.3M108.4M108.0M105.6M
2017104.5M111.4M112.8M113.4M
201699.8M103.4M105.5M103.4M
201587.1M83.7M85.4M93.0M
201493.8M99.3M103.6M105.6M
201372.2M73.4M76.4M75.1M
201267.4M70.9M67.2M71.4M
201154.8M56.5M61.1M64.8M
201044.0M47.8M51.7M55.6M
200900040.1M

Tracking the Latest Insider Buys and Sells of Anika Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 01, 2023
nunes anne
acquired
-
-
2,491
svp, chief operations officer
Oct 01, 2023
nunes anne
sold (taxes)
-13,637
18.63
-732
svp, chief operations officer
Aug 10, 2023
levitz michael l
acquired
-
-
3,859
evp, cfo, treasurer
Aug 10, 2023
levitz michael l
sold (taxes)
-21,051
18.58
-1,133
evp, cfo, treasurer
Jun 14, 2023
thompson jeffery s
acquired
-
-
6,500
-
Jun 14, 2023
vogt susan l n
acquired
-
-
6,500
-
Jun 14, 2023
fischetti gary p
acquired
-
-
6,500
-
Jun 14, 2023
conley sheryl l
acquired
-
-
6,500
-
Jun 14, 2023
larsen glenn r.
acquired
-
-
6,500
-
Jun 14, 2023
henneman john b iii
acquired
-
-
6,500
-

1–10 of 50

Which funds bought or sold ANIK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
13.05
361,000
1,323,000
0.11%
Feb 15, 2024
Meros Investment Management, LP
new
-
1,131,840
1,131,840
0.54%
Feb 15, 2024
Virtus Fund Advisers, LLC
sold off
-100
-65,019
-
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-71.15
-145,585
78,720
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
838
838
-%
Feb 15, 2024
Financial Gravity Asset Management, Inc.
unchanged
-
-
73.00
-%
Feb 15, 2024
BARCLAYS PLC
added
41.33
359,000
858,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-10.79
29,393
375,091
-%
Feb 15, 2024
Virtus Investment Advisers, Inc.
unchanged
-
183,683
1,032,820
0.77%
Feb 14, 2024
OCCUDO QUANTITATIVE STRATEGIES LP
new
-
247,538
247,538
0.03%

1–10 of 48

Are Funds Buying or Selling ANIK?

Are funds buying ANIK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANIK
No. of Funds

Unveiling Anika Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.22%
764,045
SC 13G/A
Feb 09, 2024
dimensional fund advisors lp
5.6%
821,452
SC 13G/A
Feb 09, 2024
trigran investments, inc.
14.6%
2,139,054
SC 13G/A
Jan 24, 2024
blackrock inc.
9.5%
1,383,877
SC 13G/A
Jan 22, 2024
state street corp
2.11%
309,041
SC 13G/A
Oct 06, 2023
blackrock inc.
9.7%
1,416,135
SC 13G/A
Sep 11, 2023
caligan partners lp
7.4%
1,081,360
SC 13D/A
Aug 17, 2023
caligan partners lp
6.2%
902,086
SC 13D
Feb 14, 2023
ameriprise financial inc
1.25%
181
SC 13G/A
Feb 10, 2023
dimensional fund advisors lp
6.6%
959,746
SC 13G/A

Recent SEC filings of Anika Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Jan 24, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
S-8 POS
Employee Benefits Plan
Jan 19, 2024
S-8
Employee Benefits Plan
Jan 12, 2024
3/A
Insider Trading

What is the Fair Value of ANIK?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Anika Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.1B
40.1B
0.08% 5.41%
36.19
5.16
-8.12% -17.45%
70.3B
19.5B
1.90% -2.48%
56
3.61
4.02% -22.04%
24.2B
3.8B
13.67% -2.23%
66.83
6.37
-1.48% -28.97%
21.3B
14.9B
3.05% 1.38%
8.03
1.43
2.01% 209.17%
MID-CAP
10.0B
12.7B
2.56% -12.12%
22.51
0.79
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.59
3.72
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.84
2.68
4.97% 18.89%
7.1B
3.9B
-8.15% -6.44%
-32.48
1.81
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-287.71
10.08
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.13
0.4
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.41
0.33
7.95% -543.98%
363.5M
163.3M
8.18% -20.52%
-14.79
2.23
7.14% -56.09%
238.7M
329.5M
3.17% -52.24%
-16.91
0.72
0.49% 64.22%
74.1M
50.3M
4.50% -30.54%
-4.89
1.47
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.37
1.19
5.77% 8.23%

Anika Therapeutics Inc News

Latest updates
MarketBeat17 minutes ago
Quartz3 months ago
Insider Monkey4 months ago

Anika Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-6.4%41,465,00044,302,00037,924,00039,622,00040,264,00039,657,00036,693,00035,821,00039,536,00038,145,00034,292,00032,688,00031,694,00030,678,00035,397,00029,772,00029,697,00030,418,00024,723,00026,956,00026,787,000
Gross Profit-13.9%24,944,00028,972,00022,843,00024,131,00022,779,00024,862,00021,804,00018,134,00023,023,00020,812,00020,974,00016,745,00017,343,00013,742,00021,197,00021,123,00023,746,00023,582,00017,412,000--
Costs and Expenses0.0%32,618,00032,603,00035,396,00030,798,00028,577,00028,243,00025,358,00027,257,00021,723,00011,632,00019,716,00034,697,00025,270,00023,278,00014,103,000-3,777,00017,648,00018,503,00019,241,000-14,086,00018,214,000
  S&GA Expenses4.8%24,827,00023,689,00026,996,00023,049,00021,276,00021,268,00019,201,00020,432,00017,500,00017,989,00018,175,00015,179,00015,903,00014,550,00014,431,00012,237,0007,539,0007,502,0007,672,0006,129,0005,700,000
  R&D Expenses-12.6%7,791,0008,914,0008,400,0007,749,0007,301,0006,975,0006,157,0006,000,0007,673,0007,293,0006,361,0007,632,0005,217,0004,532,0006,050,0004,084,0004,158,0004,165,0004,258,0004,064,0004,232,000
EBITDA Margin-7.2%-0.13-0.13-0.13-0.08-0.10-0.050.030.060.00-0.10-0.23-0.17---------
Income Taxes-54.3%-463,000-300,000-1,664,000-1,504,000-1,187,000-400,000-775,000-3,380,500700,0002,600,000-1,623,000-2,513,000-1,700,000-1,997,0001,600,0001,133,0003,300,0003,000,0001,473,0002,595,5001,496,000
Earnings Before Taxes-129.3%-7,039,000-3,070,000-12,014,000-6,391,000-5,362,000-3,285,000-3,708,000-9,170,0001,252,0009,130,0001,215,000-18,137,000-8,155,000-9,705,0007,373,0005,162,00012,531,00012,448,0005,980,00010,313,0009,095,000
EBT Margin-5.5%-0.17-0.17-0.17-0.12-0.14-0.10-0.020.02-0.05-0.12-0.27-0.22---------
Net Income-139.9%-6,576,000-2,741,000-10,350,000-4,908,000-4,175,000-2,843,000-2,933,000-5,793,000558,0006,531,0002,838,000-15,657,000-6,411,000-7,708,0005,793,0004,051,0009,200,0009,435,0004,507,0007,717,0007,599,000
Net Income Margin-10.0%-0.15-0.14-0.14-0.10-0.10-0.07-0.010.03-0.04-0.09-0.21-0.18---------
Free Cashflow158.9%5,744,000-9,750,000-5,007,000-2,048,0001,018,0001,148,000-3,195,0003,345,000778,0001,979,000-2,848,0002,138,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.2%328329339349348354342348353363362366416441399331320287307279269
  Current Assets3.0%157152160170168168165169166178173177202221161234224190210203196
    Cash Equivalents8.6%71.0065.0080.0086.0088.0091.0090.0094.0091.0097.0095.0096.0010411766.0015710369.0096.0089.0082.00
  Inventory2.6%44.0043.0041.0040.0037.0035.0035.0036.0035.0043.0043.0046.0048.0046.0043.0022.0025.0023.0023.0021.0024.00
  Net PPE-4.3%46.0048.0049.0048.0047.0048.0048.0048.0049.0050.0049.0051.0052.0053.0054.0051.0052.0053.0053.0054.0055.00
  Goodwill-2.9%7.007.007.007.007.007.008.008.008.008.008.008.0032.0034.0034.008.007.008.008.008.008.00
  Current Liabilities19.6%28.0023.0029.0028.0026.0029.0027.0030.0029.0041.0047.0037.0031.0028.0026.0016.0011.0010.0012.0011.009.00
  Long Term Debt-------------25.0050.00-------
    LT Debt, Non Current-------------25.0050.00-------
Shareholder's Equity-1.3%270274278286285286286287290287277272284288294288282251269264255
  Retained Earnings-3.3%191198200211216220223226231231224221237244251245241232223218211
  Additional Paid-In Capital4.2%86.0082.0083.0081.0077.0073.0069.0067.0064.0061.0057.0055.0053.0051.0048.0049.0046.0024.0052.0051.0050.00
Shares Outstanding-0.1%15.0015.0015.0015.0015.0015.0014.0014.0014.0014.0014.0014.00---------
Float------322---620---531---570---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations178.2%6,485-8,293-3,6184812,7093,088-1,8694,4722,0624,294-2,4312,5875,8653,5681,04513,02210,0515,4708,46210,01310,842
  Share Based Compensation-14.2%3,5614,1503,7173,8133,8764,0812,5453,1662,8632,7972,2591,4331,9202,240-2071,9471,3111,4431,3869821,177
Cashflow From Investing49.1%-741-1,457-1,389-2,529-1,691-1,940-1,326-1,240-1,295-2,3171,73416,8096,729-2,299-92,50341,0242,100-1,516-1,917-2,581-55,143
Cashflow From Financing97.8%-110-4,943-1,613667-4,611-46.00-86260.00-6,982594-451-28,112-25,17949,658-14127821,699-30,000-119-55.00-
  Buy Backs-100.0%-5,050---------------30,000--1.00

ANIK Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue$ 41,465$ 40,264$ 123,691$ 116,614
Cost of revenue16,52117,48546,93247,169
Gross Profit24,94422,77976,75969,445
Operating expenses:    
Research and development7,7917,30125,10520,433
Selling, general and administrative24,82721,27675,51261,745
Total operating expenses32,61828,577100,61782,178
Loss from operations(7,674)(5,798)(23,858)(12,733)
Interest and other income, net6354361,735378
Loss before income taxes(7,039)(5,362)(22,123)(12,355)
Benefit from income taxes(463)(1,187)(2,456)(2,404)
Net income (loss)$ (6,576)$ (4,175)$ (19,667)$ (9,951)
Net loss per share:    
Basic (in dollars per share)$ (0.45)$ (0.29)$ (1.34)$ (0.68)
Diluted (in dollars per share)$ (0.45)$ (0.29)$ (1.34)$ (0.68)
Weighted average common shares outstanding:    
Basic (in shares)14,63514,60314,65914,542
Diluted (in shares)14,63514,60314,65914,542
Net income (loss)$ (6,576)$ (4,175)$ (19,667)$ (9,951)
Foreign currency translation adjustment(407)(851)(121)(1,779)
Comprehensive loss$ (6,983)$ (5,026)$ (19,788)$ (11,730)

ANIK Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 70,651$ 86,327
Accounts receivable, net34,68234,627
Inventories, net43,72439,765
Prepaid expenses and other current assets7,7218,828
Total current assets156,778169,547
Property and equipment, net45,93748,279
Right-of-use assets29,05330,696
Other long-term assets18,95117,219
Deferred tax assets1,4241,449
Intangible assets, net68,76274,599
Goodwill7,2537,339
Total assets328,158349,128
Current liabilities:  
Accounts payable8,2519,074
Accrued expenses and other current liabilities19,81318,840
Total current liabilities28,06427,914
Other long-term liabilities400398
Deferred tax liability1,9556,436
Lease liabilities27,25328,817
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively 0
Common stock, $0.01 par value; 90,000 shares authorized, 14,825 issued and 14,637 outstanding and 14,625 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively146146
Additional paid-in-capital85,85281,141
Accumulated other comprehensive loss(6,564)(6,443)
Retained earnings191,052210,719
Total stockholders’ equity270,486285,563
Total liabilities and stockholders’ equity$ 328,158$ 349,128
ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
 CEO
 WEBSITEwww.anikatherapeutics.com
 EMPLOYEES345

Anika Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Anika Therapeutics Inc? What does ANIK stand for in stocks?

ANIK is the stock ticker symbol of Anika Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anika Therapeutics Inc (ANIK)?

As of Thu Feb 22 2024, market cap of Anika Therapeutics Inc is 363.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers.

What is the fair value of ANIK stock?

You can check ANIK's fair value in chart for subscribers. The fair value of Anika Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anika Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anika Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ANIK is over valued or under valued. Whether Anika Therapeutics Inc is cheap or expensive depends on the assumptions which impact Anika Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIK.

What is Anika Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ANIK's PE ratio (Price to Earnings) is -14.79 and Price to Sales (PS) ratio is 2.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anika Therapeutics Inc's stock?

In the past 10 years, Anika Therapeutics Inc has provided -0.028 (multiply by 100 for percentage) rate of return.